Literature DB >> 23321159

Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

John T Williams1, Susan L Ingram, Graeme Henderson, Charles Chavkin, Mark von Zastrow, Stefan Schulz, Thomas Koch, Christopher J Evans, Macdonald J Christie.   

Abstract

Morphine and related µ-opioid receptor (MOR) agonists remain among the most effective drugs known for acute relief of severe pain. A major problem in treating painful conditions is that tolerance limits the long-term utility of opioid agonists. Considerable effort has been expended on developing an understanding of the molecular and cellular processes that underlie acute MOR signaling, short-term receptor regulation, and the progression of events that lead to tolerance for different MOR agonists. Although great progress has been made in the past decade, many points of contention and controversy cloud the realization of this progress. This review attempts to clarify some confusion by clearly defining terms, such as desensitization and tolerance, and addressing optimal pharmacological analyses for discerning relative importance of these cellular mechanisms. Cellular and molecular mechanisms regulating MOR function by phosphorylation relative to receptor desensitization and endocytosis are comprehensively reviewed, with an emphasis on agonist-biased regulation and areas where knowledge is lacking or controversial. The implications of these mechanisms for understanding the substantial contribution of MOR signaling to opioid tolerance are then considered in detail. While some functional MOR regulatory mechanisms contributing to tolerance are clearly understood, there are large gaps in understanding the molecular processes responsible for loss of MOR function after chronic exposure to opioids. Further elucidation of the cellular mechanisms that are regulated by opioids will be necessary for the successful development of MOR-based approaches to new pain therapeutics that limit the development of tolerance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321159      PMCID: PMC3565916          DOI: 10.1124/pr.112.005942

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  283 in total

1.  Conformational changes in the G protein Gs induced by the β2 adrenergic receptor.

Authors:  Ka Young Chung; Søren G F Rasmussen; Tong Liu; Sheng Li; Brian T DeVree; Pil Seok Chae; Diane Calinski; Brian K Kobilka; Virgil L Woods; Roger K Sunahara
Journal:  Nature       Date:  2011-09-28       Impact factor: 49.962

2.  Analgesic tolerance to high-efficacy agonists but not to morphine is diminished in phosphorylation-deficient S375A μ-opioid receptor knock-in mice.

Authors:  Gisela Grecksch; Sascha Just; Claudia Pierstorff; Anne-Katja Imhof; Laura Glück; Christian Doll; Amelie Lupp; Axel Becker; Thomas Koch; Ralf Stumm; Volker Höllt; Stefan Schulz
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

3.  Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.

Authors:  Chad E Groer; Cullen L Schmid; Alex M Jaeger; Laura M Bohn
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

4.  Quantifying ligand bias at seven-transmembrane receptors.

Authors:  Sudarshan Rajagopal; Seungkirl Ahn; David H Rominger; William Gowen-MacDonald; Christopher M Lam; Scott M Dewire; Jonathan D Violin; Robert J Lefkowitz
Journal:  Mol Pharmacol       Date:  2011-05-24       Impact factor: 4.436

5.  Agonist-selective patterns of µ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies.

Authors:  Christian Doll; Jens Konietzko; Florian Pöll; Thomas Koch; Volker Höllt; Stefan Schulz
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

6.  Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection.

Authors:  Elaine K Lau; Michelle Trester-Zedlitz; Jonathan C Trinidad; Sarah J Kotowski; Andrew N Krutchinsky; Alma L Burlingame; Mark von Zastrow
Journal:  Sci Signal       Date:  2011-08-09       Impact factor: 8.192

7.  Structural flexibility of the G alpha s alpha-helical domain in the beta2-adrenoceptor Gs complex.

Authors:  Gerwin H Westfield; Søren G F Rasmussen; Min Su; Somnath Dutta; Brian T DeVree; Ka Young Chung; Diane Calinski; Gisselle Velez-Ruiz; Austin N Oleskie; Els Pardon; Pil Seok Chae; Tong Liu; Sheng Li; Virgil L Woods; Jan Steyaert; Brian K Kobilka; Roger K Sunahara; Georgios Skiniotis
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-13       Impact factor: 11.205

Review 8.  Nanobody stabilization of G protein-coupled receptor conformational states.

Authors:  Jan Steyaert; Brian K Kobilka
Journal:  Curr Opin Struct Biol       Date:  2011-07-21       Impact factor: 6.809

Review 9.  Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human.

Authors:  Michael M Morgan; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

10.  Crystal structure of the β2 adrenergic receptor-Gs protein complex.

Authors:  Søren G F Rasmussen; Brian T DeVree; Yaozhong Zou; Andrew C Kruse; Ka Young Chung; Tong Sun Kobilka; Foon Sun Thian; Pil Seok Chae; Els Pardon; Diane Calinski; Jesper M Mathiesen; Syed T A Shah; Joseph A Lyons; Martin Caffrey; Samuel H Gellman; Jan Steyaert; Georgios Skiniotis; William I Weis; Roger K Sunahara; Brian K Kobilka
Journal:  Nature       Date:  2011-07-19       Impact factor: 49.962

View more
  320 in total

1.  Morphine drives internal ribosome entry site-mediated hnRNP K translation in neurons through opioid receptor-dependent signaling.

Authors:  Pin-Tse Lee; Po-Kuan Chao; Li-Chin Ou; Jian-Ying Chuang; Yen-Chang Lin; Shu-Chun Chen; Hsiao-Fu Chang; Ping-Yee Law; Horace H Loh; Yu-Sheng Chao; Tsung-Ping Su; Shiu-Hwa Yeh
Journal:  Nucleic Acids Res       Date:  2014-10-31       Impact factor: 16.971

2.  Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI.

Authors:  Christin Y Sander; Jacob M Hooker; Ciprian Catana; Bruce R Rosen; Joseph B Mandeville
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

3.  Design synthesis and structure-activity relationship of 5-substituted (tetrahydronaphthalen-2yl)methyl with N-phenyl-N-(piperidin-2-yl)propionamide derivatives as opioid ligands.

Authors:  Srinivas Deekonda; David Rankin; Peg Davis; Josephine Lai; Todd W Vanderah; Frank Porecca; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2015-11-23       Impact factor: 3.641

Review 4.  [Pain inhibition by opioids-new concepts].

Authors:  C Stein
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

5.  Cocaine dysregulates opioid gating of GABA neurotransmission in the ventral pallidum.

Authors:  Yonatan M Kupchik; Michael D Scofield; Kenner C Rice; Kejun Cheng; Bernard P Roques; Peter W Kalivas
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

6.  Thalidomide Promotes Morphine Efficacy and Prevents Morphine-Induced Tolerance in Rats with Diabetic Neuropathy.

Authors:  Jianhui Zhao; Hong Wang; Tieying Song; Yunliang Yang; Kunfeng Gu; Pengyu Ma; Zaiwang Zhang; Limin Shen; Jiabao Liu; Wenli Wang
Journal:  Neurochem Res       Date:  2016-08-30       Impact factor: 3.996

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Opioid Activity in the Locus Coeruleus Is Modulated by Chronic Neuropathic Pain.

Authors:  Meritxell Llorca-Torralba; Fuencisla Pilar-Cuéllar; Lidia Bravo; Cristina Bruzos-Cidon; María Torrecilla; Juan A Mico; Luisa Ugedo; Emilio Garro-Martínez; Esther Berrocoso
Journal:  Mol Neurobiol       Date:  2018-10-03       Impact factor: 5.590

9.  Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats.

Authors:  Jun-Tao Gao; Chloe J Jordan; Guo-Hua Bi; Yi He; Hong-Ju Yang; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2018-10-03       Impact factor: 7.853

Review 10.  Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.

Authors:  N T Burford; J R Traynor; A Alt
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.